PREGMAX M-75 Pregabalin / Methylcobalamin 75mg / 750mcg Capsule 1's
RXDRUG-DR-XY42036-1pc
Discreet Packaging
FDA-registered Products
FDA-licensed Pharmacies
Indications/Uses
Indicated in the management of peripheral neuropathy.
Dosage/Direction for Use
Starting Dose: 1 cap twice daily; provided this is tolerable vis-a-vis renal function. Patients previously on gabapentin will have a wash-out period of 1 week prior to start of dosing with pregabalin.
Special Precautions
Not to be given in patients w/ suspected vit B12 deficiency w/o 1st confirming diagnosis. Monitor blood regularly. Dose >10 mcg daily may produce hematological response in patients w/ folate deficiency. Leber's disease or tobacco amblyopia.
Adverse Reactions
Methylcobalamin: Allergic hypersensitivity reactions have occurred rarely after parenteral doses of the vitamin B12 compounds, cyanocobalamin and hydroxocobalamin. Antibodies to hydroxocobalamin-transcobalamin II complex have developed during hydroxocobalamin therapy. Arrhythmias secondary to hypokalemia have occurred at the beginning of parenteral treatment with hydroxocobalamin. Intranasal cyanocobalamin may cause rhinitis, nausea and headache.
Cyanocobalamin or hydroxocobalamin should, if possible, not be given to patients with suspected vitamin B12 deficiency without 1st confirming the diagnosis. Regular monitoring of the blood is advisable. Use of doses >10 mcg daily may produce a hematological response in patients with folate deficiency; indiscriminate use may mask the precise diagnosis. Conversely, folate may mask vitamin B12 deficiency. Cyanocobalamin should not be used for Leber's disease or tobacco amblyopia since these optic neuropathies may degenerate further.
Pregabalin: The most common adverse effects reported during therapy with pregabalin are dizziness and somnolence. Other common adverse effects include blurred vision, diplopia, increased appetite and weight gain, dry mouth, constipation, vomiting, flatulence, euphoria, confusion, reduced libido, erectile dysfunction, irritability, vertigo, ataxia, tremor, dysarthria, paraesthesia, fatigue and edema. Disturbances of attention, memory, coordination and gait also occur frequently. Syncope and congestive heart failure have been reported less frequently. Reversible renal failure, elevation of creatine kinase concentration and rhabdomyolysis have been reported rarely. Hypersensitivity reactions have occurred shortly after starting pregabalin therapy; symptoms include rash, blisters, urticaria, dyspnea and wheezing. Stevens-Johnson syndrome has also been reported. An increased incidence of hemangiosarcoma was observed in mice that had been given high doses of pregabalin.
Cyanocobalamin or hydroxocobalamin should, if possible, not be given to patients with suspected vitamin B12 deficiency without 1st confirming the diagnosis. Regular monitoring of the blood is advisable. Use of doses >10 mcg daily may produce a hematological response in patients with folate deficiency; indiscriminate use may mask the precise diagnosis. Conversely, folate may mask vitamin B12 deficiency. Cyanocobalamin should not be used for Leber's disease or tobacco amblyopia since these optic neuropathies may degenerate further.
Pregabalin: The most common adverse effects reported during therapy with pregabalin are dizziness and somnolence. Other common adverse effects include blurred vision, diplopia, increased appetite and weight gain, dry mouth, constipation, vomiting, flatulence, euphoria, confusion, reduced libido, erectile dysfunction, irritability, vertigo, ataxia, tremor, dysarthria, paraesthesia, fatigue and edema. Disturbances of attention, memory, coordination and gait also occur frequently. Syncope and congestive heart failure have been reported less frequently. Reversible renal failure, elevation of creatine kinase concentration and rhabdomyolysis have been reported rarely. Hypersensitivity reactions have occurred shortly after starting pregabalin therapy; symptoms include rash, blisters, urticaria, dyspnea and wheezing. Stevens-Johnson syndrome has also been reported. An increased incidence of hemangiosarcoma was observed in mice that had been given high doses of pregabalin.
Drug Interactions
Absorption of vitamin B12 from the gastrointestinal tract may be reduced by neomycin, aminosalicylic acid, histamine H2-antagonists, omeprazole and colchicine. Serum concentrations may be decreased by use of oral contraceptives. Many of these interactions are unlikely to be of clinical significance but should be taken into account when performing assays for blood concentrations. Parenteral chloramphenicol may attenuate the effect of vitamin B12 in anemia.
Storage
Store at temperatures not exceeding 30°C.
Action
Pharmacology: Pharmacokinetics: Pregabalin is rapidly absorbed after oral doses and peak plasma concentrations are achieved within 1.5 hrs. Oral bioavailability is about 90%. The rate but not the extent of absorption is reduced if given with food but this is not clinically significant. Steady-state is achieved after 1-2 days. Pregabalin is not bound to plasma proteins and undergoes negligible metabolism. About 98% of a dose is excreted in the urine as unchanged drug. The mean elimination half-life is 6.3 hrs. Pregabalin is removed by hemodialysis.
Methylcobalamin substances bind to intrinsic factor, a glycoprotein secreted by the gastric mucosa, and are then actively absorbed from the gastrointestinal tract. Absorption is impaired in patients with an absence of intrinsic factor, with a malabsorption syndrome or with disease or abnormality of the gut, or after gastrectomy. Absorption from the gastrointestinal tract can also occur by passive diffusion; little of the vitamin present in food is absorbed in this manner although the process becomes increasingly important with larger amounts eg, those used therapeutically. After intranasal dosage, peak plasma concentrations of cyanocobalamin have been reached in 1-2 hrs. The bioavailability of the intranasal preparation is about 7-11% of that by IM injection.
Vitamin B12 is extensively bound to specific plasma proteins called transcobalamins; transcobalamin II appears to be involved in the rapid transport of the cobalamins into tissues. Vitamin B12 is stored in the liver, excreted in the bile and undergoes extensive enterohepatic recycling; part of a dose is excreted in the urine, most of it in the first 8 hrs; urinary excretion, however, accounts for only a small fraction in the reduction of total body stores acquired by dietary means. Vitamin B12 diffuses across the placenta and also appears in breast milk.
Methylcobalamin substances bind to intrinsic factor, a glycoprotein secreted by the gastric mucosa, and are then actively absorbed from the gastrointestinal tract. Absorption is impaired in patients with an absence of intrinsic factor, with a malabsorption syndrome or with disease or abnormality of the gut, or after gastrectomy. Absorption from the gastrointestinal tract can also occur by passive diffusion; little of the vitamin present in food is absorbed in this manner although the process becomes increasingly important with larger amounts eg, those used therapeutically. After intranasal dosage, peak plasma concentrations of cyanocobalamin have been reached in 1-2 hrs. The bioavailability of the intranasal preparation is about 7-11% of that by IM injection.
Vitamin B12 is extensively bound to specific plasma proteins called transcobalamins; transcobalamin II appears to be involved in the rapid transport of the cobalamins into tissues. Vitamin B12 is stored in the liver, excreted in the bile and undergoes extensive enterohepatic recycling; part of a dose is excreted in the urine, most of it in the first 8 hrs; urinary excretion, however, accounts for only a small fraction in the reduction of total body stores acquired by dietary means. Vitamin B12 diffuses across the placenta and also appears in breast milk.
MedsGo Class
Drugs for Neuropathic Pain / Anticonvulsants
Features
Brand
Pregmax M-75
Full Details
Dosage Strength
75 mg / 750 mcg
Drug Ingredients
- Methylcobalamin
- Pregabalin
Drug Packaging
Capsule 1's
Generic Name
Pregabalin / Methylcobalamin
Dosage Form
Capsule
Registration Number
DR-XY42036
Drug Classification
Prescription Drug (RX)
Please sign in so that we can notify you about a reply